Sweeping Changes At CDER Recommended In IoM Drug Safety Report
This article was originally published in The Pink Sheet Daily
Executive Summary
Among solutions suggested is six-year fixed term for the FDA commissioner and appointment of external advisory board to oversee cultural changes.
You may also be interested in...
Gottlieb Promotes 'Team' Work For Product Reviews
US FDA Commissioner intends to change agency's siloed structure and move reviewers into teams that will follow products pre- and post-market.
FDA,CMS Build Drug Safety System Prototype
Coming Medicare final rule enables FDA to access Part D data for public health and safety research.
FDA,CMS Build Drug Safety System Prototype
Coming Medicare final rule enables FDA to access Part D data for public health and safety research.